GSK set to receive over $500M from mRNA patent settlement tied to BioNTech–CureVac–Pfizer deal

GSK will receive an upfront settlement of $370 million connected to the CureVac–BioNTech mRNA patent settlement in the U.S., with $320 million paid in cash and the remainder as value from an amendment to the GSK–CureVac agreement32.

GSK will also receive a 1% royalty on future U.S. sales by Pfizer/BioNTech of influenza, COVID‑19, and related combination mRNA vaccine products from the beginning of 202532.

CureVac and GSK together are set to receive an aggregate $740 million plus single‑digit royalties on U.S. COVID‑19 vaccine sales going forward under the settlement framework with BioNTech and Pfizer4.

Industry coverage notes GSK’s immediate cash inflow of $320 million from the settlement, aligning with GSK’s disclosed breakdown of the $370 million upfront52.

Analysts and trade press frame the deal as reducing GSK’s future royalties payable to CureVac for its own mRNA programs, due to amendments in their existing agreement13.

Taken together, GSK’s secured $370 million upfront plus ongoing 1% U.S. royalties indicate GSK is set for well over $500 million in total value over time, depending on Pfizer/BioNTech U.S. mRNA vaccine sales volumes31.

Sources:

1. https://www.pharmexec.com/view/gsk-gains-370-million-upfront-reduced-royalties-curevac-mrna-patent-settlement-agreement-pfizer-biontech

2. https://www.gsk.com/media/p3dnhgc4/final-curevacbiontech-mrna-patent-litigation-080725.pdf

3. https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-us-settlement-of-curevacbiontech-mrna-patent-litigation/

4. https://www.curevac.com/en/curevac-announces-resolution-of-patent-litigation-with-pfizer-biontech/

5. https://www.marshallip.com/news/marshall-gerstein-counsels-curevac-through-global-resolution-of-patent-litigation-with-pfizer-biontech/